Ibudilast affects brain atrophy in PPMS, not SPMS

In the randomised phase 2 trial SPRINT-MS, the effect of ibudilast on brain measures of integrity was evaluated in both primary and secondary progressive MS (PPMS and SPMS). Results of a post-hoc analysis suggested that the effect of ibudilast on...

Post-study immunotherapy confounds primary survival outcome

An exploratory analysis of the phase 3 MYSTIC trial suggests that the high rate of subsequent post-study immunotherapy received by patients with metastatic non-small cell lung cancer (NSCLC) who previously received chemotherapy, confounded the primary overall survival (OS) outcome. Durvalumab...

Head-to-head comparison of two ALK inhibitors

Brigatinib showed a statistically and clinically relevant improvement in PFS vs crizotinib in patients with anaplastic lymphoma kinase (ALK) inhibitor-naïve, ALK-positive non-small cell lung cancer (NSCLC). This was the result of the first interim analysis from the ALTA-1L study comparing the...